Advances in targeted therapy for gastric cancer based on tumor driver genes
10.3724/zdxbyxb-2023-0522
- VernacularTitle:靶向肿瘤驱动基因的胃癌治疗研究进展
- Author:
Shiying WU
1
;
Pinglong XU
;
Fei ZHANG
Author Information
1. 浙江工商大学食品与生物工程学院,浙江 杭州 310018;浙江大学生命系统稳态与保护教育部重点实验室 浙江省癌症分子细胞生物学重点实验室,浙江 杭州 310058
- Keywords:
Gastric cancer;
Tumor driver genes;
Targeted therapy;
Clinical trials;
Review
- From:
Journal of Zhejiang University. Medical sciences
2024;53(1):73-83
- CountryChina
- Language:Chinese
-
Abstract:
As the understanding of the pathogenic mechanisms of gastric cancer deepens and the identification of gastric cancer driver genes advances,drugs targeting gastric cancer driver genes have been applied in clinical practice.Among them,trastuzumab,as the first targeted drug for gastric cancer,effectively inhibits the proliferation and metastasis of tumor cells by targeting overexpressed human epidermal growth factor receptor 2(HER2).Trastuzumab has become the standard treatment for HER2-positive gastric cancer patients.Ramucirumab,on the other hand,inhibits tumor angiogenesis by targeting vascular endothelial growth factor receptor 2(VEGFR2)and has been used as second-line therapy for advanced gastric cancer patients.In addition,bemarituzumab targets overexpressed fibroblast growth factor receptor 2(FGFR2),while zolbetuximab targets overexpressed claudin 18.2(CLDN18.2),significantly extending progression-free survival and overall survival in patients with gastric cancer in clinical trials.This article reviews the roles of tumor driver genes in the progression of gastric cancer,and the treatment strategies for gastric cancer primarily based on targeting HER2,VEGF,FGFR2,CLDN18.2 and MET.This provides a reference for clinical application of targeted therapy for gastric cancer.
